HYBRIGENICS : green ligt for two European patents protecting new oral formulations of inecacitol

Press Release

Hybrigenics : green light for two European patents protecting new oral formulations of inecalcitol Hybrigenics obtains patent protection until 2031 for innovative oral formulations optimized for the delivery of high doses of inecalcitol

Paris, October 9th, 2012 - Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces it has received from the European Patent Office the official notification of its intent to grant, after an accelerated examination procedure, two patents on new pharmaceutical formulations allowing a better absorption of inecalcitol.
One patent covers innovative tablets, an unusual formulation for a vitamin D receptor agonist like inecalcitol. The other patent protects a second generation of soft gelatin capsules with a higher concentration of inecalcitol. The chronic lymphocytic leukemia patients treated in the ongoing Phase II clinical study of inecalcitol receive one 2-milligram tablet every day.
Filed in 2010 (cf Hybrigenics' press release of November 2nd, 2010), this patent application has been reviewed and approved in just 2 years by the European Patent Office, like two other patent applications on the therapeutic use of high doses of inecalcitol (cf Hybrigenics' press release of January 24th, 2011) and on a key step in the chemical synthesis of inecalcitol (cf Hybrigenics' press release of February 27th, 2012). All other examinations are progressing smoothly for the rest of the world under the normal PCT or American procedures.
"Our patenting strategy has proved to be relevant and its execution extremely efficient, given the approval rate and speed of examinations," explained Rémi Delansorne, Hybrigenics' CEO. "Hybrigenics now definitively owns four patent families ensuring exclusive commercialization of oral inecalcitol up to 2031."

About Hybrigenics : Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold- standard chemotherapeutic treatment for this indication. Oral inecalcitol has recently been studied in a clinical trial for the treatment of moderate-to-severe psoriasis, and is currently being tested in chronic lymphocytic leukemia patients. Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary, is the market leader in Yeast Two- Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

*** HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris ISIN: FR0004153930 - Ticker: ALHYG Hybrigenics Rémi Delansorne CEO

Tel.: [phone]

[e-mail]

NewCap.

Financial communication

Axelle Vuillermet / Pierre Laurent

Tel.: [phone] [e-mail]